Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors

INTRODUCTION: Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptom (LUTS) development in men [1]. The intensity of the symptoms may vary from mild to severe, significantly affecting the quality of life. Erectile dysfunction (ED) is one of the most challenging is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolontarev, Konstantin, Govorov, Alexander, Kasyan, George, Priymak, Diana, Pushkar, Dmitry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2016
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260456/
https://www.ncbi.nlm.nih.gov/pubmed/28127458
http://dx.doi.org/10.5173/ceju.2016.879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260456/
https://www.ncbi.nlm.nih.gov/pubmed/28127458
http://dx.doi.org/10.5173/ceju.2016.879

Ejemplares similares